NurExone Biologic Wins Healthcare Award, Announces Investor Outreach Partnership

NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) announced it received first place in the Healthcare category at the BOLD Awards VII Gala held March 27, 2026, in Barcelona, recognizing its leadership in exosome-based therapies for central nervous system injuries. The award selection was made by a panel of global industry leaders, highlighting the company's innovative approach to treating central nervous system injuries through regenerative exosome-based therapies. This recognition comes as the company advances its lead product, ExoPTEN, which has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury.

The company further reported plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval, to support investor awareness efforts beginning April 1, 2026. This partnership will include distribution of news and updates across more than 5,000 outlets, with a monthly fee of $6,500 under a one-year agreement aimed at strengthening market visibility and long-term shareholder value. The investor outreach initiative represents a strategic move to increase awareness of NurExone's progress in developing therapies for central nervous system injuries, particularly as the company approaches clinical trials in the U.S. and Europe.

NurExone's regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the roadmap towards clinical trials. The company's focus on exosome-based therapies addresses a significant unmet medical need in treating central nervous system injuries, where current treatment options remain limited. The BOLD Awards recognition validates the company's scientific approach and positions it as a leader in this emerging therapeutic area. The award selection process involved evaluation by industry experts who recognized the potential impact of NurExone's technology on patient outcomes.

The engagement with Investor Brand Network will provide NurExone with access to a specialized communications platform that delivers article and editorial syndication to 5,000+ outlets, enhanced press release distribution, and social media distribution to millions of followers. This comprehensive investor relations strategy is designed to effectively communicate the company's progress to investors, analysts, and the broader financial community. The partnership comes at a critical time as NurExone advances its clinical development programs and seeks to build shareholder value through increased market awareness.

NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy. The company's commercial strategy includes offering solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications beyond central nervous system injuries. The combination of industry recognition through the BOLD Awards and enhanced investor communication through the IBN partnership positions NurExone to accelerate its development timeline and potentially bring innovative therapies to patients suffering from spinal cord and optic nerve injuries. For more information about the company's technology and development programs, visit https://nurexone.com/.